Wyeth Normiflo low molecular weight heparin approved by FDA May 23.
Executive Summary
WYETH-AYERST NORMIFLO LOW MOLECULAR WEIGHT HEPARIN CLEARS FDA May 23 for prevention of deep vein thrombosis in knee replacement surgery patients. Normiflo (aldeparin) will be the third low molecular weight heparin on the market. Rhone-Poulenc Rorer markets Lovenox for hip and knee replacement procedures and recently received clearance for use of the product in abdominal surgery ("The Pink Sheet" May 19, T&G-6). Pharmacia & Upjohn markets Fragmin for abdominal surgery and has filed for hip replacement.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth